Immunocompromised Host

Download PDF

Recent Publications on Immunocompromised Host:
[Lymphoma in patients who have undergone organ transplantation: severe and variable clinical presentation] Two patients presented with post-transplant lymphoproliferative disorder...	11th July, 2008	Afd. Hematologie, Universitair Medisch Centrum Groningen, Postbus 30.001,	Ned Tijdschr Geneeskd. 2008 May 10;152(19):1077-80.
Human herpesvirus 8 infections in patients with immunodeficiencies. In 1994, Chang et al described a novel herpesvirus in tissues from...	9th July, 2008	Service d'Anatomie et Cytologie Pathologiques, CHU Purpan, Universite	Hum Pathol. 2008 Jul;39(7):983-93. DOI Direct Link
QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. Tuberculin skin test (TST) has been used for 100 years for the diagnosis...	5th July, 2008	Provincial Laboratory for Public Health Microbiology, University of	Expert Rev Mol Diagn. 2008 May;8(3):247-56. DOI Direct Link
Bibliography. Current world literature. Infections of the immunocompromised host. Tuberculin skin test (TST) has been used for 100 years for the diagnosis...	4th July, 2008		Curr Opin Infect Dis. 2008 Aug;21(4):445-52.
Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor. Severe combined immunodeficiencies (SCID) are disorders with impairment of...	4th July, 2008	Division of Allergy and Immunology, Department of Pediatrics, Faculty of	Asian Pac J Allergy Immunol. 2008 Mar;26(1):71-5.
→View more research publications.

BioNews Results for Immunocompromised Host:
CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ(R), Merck's Rotavirus Vaccine	SmartBrief:  Jun 25 2008 8:34PM Matching: immunocompromised host
CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ(R), Merck's Rotavirus Vaccine	Yahoo! Canada:  Jun 25 2008 7:43PM Matching: immunocompromised host
CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ(R), Merck's Rotavirus Vaccine	Stockwatch:  Jun 25 2008 7:01PM Matching: immunocompromised host

Immunocompromised Host Clinical Trials:
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections	Mycoses Intervention: Drug: Voriconazole
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia	Fungal Infection
Surveillance of Fungal Infections During Construction Activity
Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness	Upper Respiratory Tract Infection;   Lower Respiratory Tract Infection
→View more trials.

Immunocompromised Host Patents:
US Patent No.	Title
6894056	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
7067621	Multifunctional context-activated protides and methods of use
7078435	Autoinducer compounds
7087661	Safe and effective biofilm inhibitory compounds and health-related uses thereof
7098238	Degradation fragments
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Immunocompromised Host scientists - we have details of around 1000 individuals working on Immunocompromised Host .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.